Why Teva Pharmaceuticals (TEVA) is Crashing? A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company.

Teva hit with $503 mln EU antitrust fine for disparaging rival product October 31, 2024 Teva Pharmaceutical Industries Ltd has agreed to pay $450 million to resolve allegations it used charities ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares opened today at $17.99. According to TipRanks ...

17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of T Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinicsThe program ...

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $21.78.

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Teva Pharmaceutical reports fourth-quarter revenue ... including surpassing the outlook for our key innovative products, growing our generics business across all segments, and accelerating our ...